Prevention of torsade de pointes in hospital settings: A scientific statement from the American heart association and the American college of cardiology foundation

Circulation

Volumn 121, Issue 8, 2010, Pages 1047-1060

  Drew, Barbara J ^a   Ackerman, Michael J ^a   Funk, Marjorie ^a   Gibler, W Brian ^a   Kligfield, Paul ^a   Menon, Venu ^a   Philippides, George J ^a   Roden, Dan M ^a   Zareba, Wojciech ^a  

^a NONE

Author keywords

Acute care; AHA Scientific Statements; Arrhythmia; Drugs; Electrocardiography; Electrophysiology; Torsade de pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ARSENIC TRIOXIDE; BEPRIDIL; CHLOROQUINE; CITALOPRAM; CLARITHROMYCIN; DISOPYRAMIDE; DOFETILIDE; DROPERIDOL; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; HALOPERIDOL; IBUTILIDE; IBUTILIDE FUMARATE; MAGNESIUM SULFATE; METHADONE; MOXIFLOXACIN; PAROXETINE; POTASSIUM; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; PROCAINAMIDE; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE POLYGALACTURONATE; RANOLAZINE; SOTALOL; TERFENADINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; VERAPAMIL; VOLTAGE GATED SODIUM CHANNEL;

ARRHYTHMOGENESIS; CARDIOVERSION; DOSE RESPONSE; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; ELECTROCARDIOGRAPHY MONITORING; GENE; GENETIC SUSCEPTIBILITY; GROUPS BY AGE; HEART ATRIUM PACING; HEART REPOLARIZATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE PACING; HOSPITAL PATIENT; HUMAN; INCIDENCE; KCNH 2 GENE; KCNQ 1 GENE; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SCN 5A GENE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TORSADE DES POINTES; UNITED STATES;

ELECTROCARDIOGRAPHY; HEART RATE; HOSPITAL UNITS; HUMANS; MONITORING, PHYSIOLOGIC; RISK FACTORS; TORSADES DE POINTES; UNITED STATES;

EID: 77649245968     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.192704     Document Type: Review

References (114)

1. Dessertenne F. La tachycardie ventriculaire á deux foyers opposes variables. Arch Mal Coeur Vaiss. 1966;59:263-272.
2. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806-817.
3. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, Robinson JL, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
4. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome: International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339:960-965.
5. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348: 1866-1874.
6. Sauer AJ, Moss AJ, McNitt S, Peterson DR, Zareba W, Robinson JL, Qi M, Goldenberg I, Hobbs JB, Ackerman MJ, Benhorin J, Hall WJ, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329-337.
7. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088-1093.
8. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the car-diotoxic actions of terfenadine. JAMA. 1993;269:1532-1536.
9. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2007;63: 216-223.
10. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsa-dogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol. 2006;17:337-340.
11. Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M, Belhassen B, Hochenberg M, Viskin S. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol. 2007;49:320-328.
12. Kawabata M, Hirao K, Takeshi S, Sakurai K, Inagaki H, Hachiya H, Isobe M. Torsades de pointes related to transient marked QT prolongation following successful emergent percutaneous coronary intervention for acute coronary syndrome. J Electrocardiol. 2008;41: 117-122.
13. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, Volders PG, Vos MA. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation. 2004;110:2453-2459.
14. Zareba W, Moss AJ, le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol. 1994;23:1541-1546.
15. Zareba W. Drug induced QT prolongation. Cardiol J. 2007;14:523-533.
16. Akar FG, Yan GX, Antzelevitch C, Rosenbaum DS. Unique topographical distribution of M cells underlies reentrant mechanism of torsades de pointes in the long-QT syndrome. Circulation. 2002;105: 1247-1253.
17. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:43-51. (Pubitemid 34073163)
18. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci. 2003;24:619-625.
19. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridimensional activation patterns. Circulation. 1997;96:4392-4399.
20. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
21. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.
22. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol. 2006;47:764-768.
23. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, Gerorge AL Jr, Roden DM. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002; 105:1943-1948.
24. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm. 2007;4:603-607.
25. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med. 2004;82:182-188.
26. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm. 2005;2(suppl): S30-S37.
27. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, Cappuccio FP, Sagnella GA, Kass RS, Keating MT. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 2002;297:1333-1336.
28. Burke A, Creighton W, Mont E, Li L, Hogan S, Kutys R, Fowler D, Virmani R. Role of SCN5A Y1102 polymorphism in sudden cardiac death in blacks. Circulation. 2005;112:798-802.
29. Plant LD, Bowers PN, Liu QY, Morgan T, Zhang T, State MW, Chen W, Kittles RA, Goldstein SA. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest. 2006;116:430-435.
30. Van Norstrand DW, Tester DJ, Ackerman MJ. Overrepresentation of the proarrhythmic, sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. Heart Rhythm. 2008;5:712-715.
31. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97: 175-187.
32. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003;78:1479-1487.
33. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases? The intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1120-1121.
34. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48:e247-e346.
35. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation. 1971;44:130-142.
36. Wald RW, Waxman MB, Colman JM. Torsades de pointes ventricular tachycardia: a complication of disopyramide shared with quinidine. J Electrocardiol. 1981;14:301-307.
37. Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, Ruo TI, Asada A, Talano JV, Atkinson AJ Jr. Torsade de pointes induced by N-acetylprocainamide. J Am Coll Cardiol. 1984;4:621-624.
38. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990;65:74A-81A.
39. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ; Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865.
40. Murray KT. Ibutilide. Circulation. 1998;97:493-497.
41. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501-504.
42. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070.
43. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med. 1993;119:391-394.
44. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electro-cardiographic consequences. JAMA. 1993;269:1513-1518.
45. Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
46. Pinto YM, Van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet. 1999; 353:980. (Pubitemid 29132610)
47. Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by eryth-romycin. Chest. 1994;105:368-372.
48. Von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234-240.
49. c interval screening in methadone treatment. Ann Intern Med. 2009;150:387-395.
50. Tarabar AF, Hoffman RS, Nelson LS. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol. 2008;4:101-105.
51. Chung KJ, Wang YC, Liu BM, Supernaw RB. Management of ventricular dysrhythmia secondary to trazadone overdose. J Emerg Med. 2008; 35:171-174.
52. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsy-chotic drugs and the risk of sudden cardiac death [published correction appears in N Engl J Med. 2009;361:1814]. N Engl J Med. 2009;360: 225-235.
53. Lazzara R. Amiodarone and torsade de pointes. Ann Intern Med. 1989; 111:549-551.
54. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res. 1984;55:278-285.
55. Yang T, Snyders D, Roden DM. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38: 737-744.
56. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, DiDiego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910. (Pubitemid 39136212)
57. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310:599-605.
58. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116:1647-1652.
59. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res. 1993;27:2186-2193.
60. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, Oliver WC, Narr BJ, Ackerman MJ. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anes-thesiology. 2007;107:531-536.
61. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR; Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475-495.
62. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39-43.
63. Roden DM. Taking the "Idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029-1034.
64. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore). 2003;82:282-290.
65. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
66. Mank-Seymour AR, Richmond JL, Wood LS, Reynolds JM, Fan YT, Warnes GR, Milos PM, Thompson JF. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J. 2006;152:1116-1122.
67. Modell SM, Lehmann MH. The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med. 2006;8:143-155.
68. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pin-navaia A, Acquaro G, Priori SG. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol. 2000;11:691-696.
69. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025-2032.
70. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259:59-69.
71. Elming H, Brendorp B, Kober L, Sahebzadah N, Torp-Petersen C. QTc interval in the assessment of cardiac risk. Card Electrophysiol Rev. 2002;6:289-294.
72. Houltz B, Darpö B, Edvardsson N, Blomström P, Brachmann J, Crijns HJ, Jensen SM, Svernhage E, Vallin H, Swedberg K. Electrocardio-graphic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol. 1998;21:1044-1057.
73. Pedersen HS, Elming H, Seibaek M, Burchardt H, Brendorp B, Torp-Pedersen C, Køber L. Risk factors and predictors of torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol. 2007;100:876-880.
74. Singh BN. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am J Cardiol 1992;69: 68D-74D.
75. Aström-Lilja C, Odeberg JM, Ekman E, Hägg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Phar-macoepidemiol Drug Saf. 2008;17:587-592.
76. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med. 2006;17:254-259.
77. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197-200.
78. Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, Raebel MA, Platt R. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15: 361-368.
79. Justo D, Zeltser D. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports. Mycoses. 2006;49:463-470.
80. Roe CM, Odell KW, Henderson RR. Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol. 2003;23:197-200.
81. Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 2001;24: 575-585.
82. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998;280:1774-1776.
83. Ebert SN, Liu XK, Woosley RL. Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health. 1998;7:547-557.
84. Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. 2005;111:171-176.
85. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
86. Yasuda M, Nakazato Y, Sasaki A, Kawano Y, Nakazato K, Tokano T, Daida H. Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter. Circ J. 2006;70:662-666.
87. Roden DM. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolar-ization. Eur Heart J. 1993;14(suppl H):56-61.
88. Eriksson JW, Carlberg B, Hillörn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med. 1999; 245:307-310.
89. Roden DM, Iansmith DH. Effects of low potassium or magnesium concentrations on isolated cardiac tissue. Am J Med. 1987;82:18-23.
90. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149-2154.
91. Keren A, Tzivoni D. Torsades de pointes: prevention and therapy. Cardiovasc Drugs Ther. 1991;5:509-513.
92. White CM, Xie J, Chow MS, Kluger J. Prophylactic magnesium to decrease the arrhythmogenic potential of class III antiarrhythmic agents in a rabbit model. Pharmacotherapy. 1999;19:635-640.
93. Lüderitz B, Manz M. The value of magnesium in intensive care medicine [in German]. Z Kardiol. 1994;83(suppl 6):121-126.
94. Nakasone H, Sugama R, Sakugawa H, Matayoshi R, Miyagi T, Maeshiro T, Yamashiro T, Higa F, Hokama A, Kinjo F, Saito A, Toda T. Alcoholic liver cirrhosis complicated with torsade de pointes during plasma exchange and hemodiafiltration. J Gastroenterol. 2001;36: 564-568.
95. Daya SK, Gowda RM, Khan IA. Ciprofloxacin-and hypocalcemia-induced torsade de pointes triggered by hemodialysis. Am J Ther. 2004; 11:77-79.
96. Akiyama T, Batchelder J, Worsman J, Moses HW, Jedlinski M. Hypocalcemic torsades de pointes. J Electrocardiol. 1989;22:89-92.
97. Fiset C, Drolet B, Hamelin BA, Turgeon J. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther. 1997; 283:148-156.
98. Díiaz-Castro O, Puchol A, Almendral J, Torrecilla EG, Arenal A, Martínez-Selles M. Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia. J Electrocardiol. 2004;37:55-60.
99. Raviña T, Raviña P, Gutierrez J. Acquired long QT syndrome: risperidone-facilitated triggered activity and torsades de pointes during complete AV block: I. Int J Cardiol. 2007;116:416-420.
100. Darbar D, Kimbrough J, Jawaid A, McCray R, Ritchie MD, Roden DM. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol. 2008;51:836-842.
101. Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002;48:3-9.
102. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993;72:17B-22B.
103. Batchvarov V, Malik M. Individual patterns of QT/RR relationship. Card Electrophysiol Rev. 2002;6:282-288.
104. Helfenbein ED, Zhou SH, Lindauer JM, Field DQ, Gregg RE, Wang JJ, Kresge SS, Michaud FP. An algorithm for continuous real-time QT interval monitoring. J Electrocardiol. 2006;39(suppl):S123-S127.
105. Sommargren C, Drew BJ. Preventing torsades de pointes by careful cardiac monitoring in hospital settings. AACN Adv Crit Care. 2007;18: 285-293.
106. Postema PG, De Jong JS, Van der Bilt IA, Wilde AA. Accurate elec-trocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm. 2008;5:1015-1018.
107. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurión OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2:569-574.
108. Kligfield P, Gettes LS, Bailey JJ, Childers R, Deal BJ, Hancock EW, van Herpen G, Kors JA, Macfarlane P, Mirvis DM, Pahlm O, Rautaharju P, Wagner GS. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology; and the Heart Rhythm Society. Circulation. 2007;115:1306-1324. (Pubitemid 46594775)
109. Kligfield P, Hancock EW, Helfenbein ED, Dawson EJ, Cook MA, Lindauer JM, Zhou SH, Xue J. Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs. Am J Cardiol. 2006;98:88-92.
110. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Sommargren C, Swiryn S, Van Hare GF. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young. Circulation. 2004;110:2721-2746.
111. Drew BJ, Funk M. Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation. Crit Care Nurs Clin North Am. 2006;18:157-168.
112. Kowey PR, Vanderlugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol. 1996;78(8A):46-52.
113. Banai S, Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol. 1993;4:206-210.
114. Pinski SL, Eguía LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol. 2002;25:1612-1615.